MAZE Key Statistics, Chart & Performance
The current stock price of MAZE is 46.53 USD. In the past month the price increased by 17%. In the past year, price increased by 247.76%.
MAZE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MAZE. When comparing the yearly performance of all stocks, MAZE is one of the better performing stocks in the market, outperforming 98.6% of all stocks.
MAZE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MAZE. No worries on liquidiy or solvency for MAZE as it has an excellent financial health rating, but there are worries on the profitability.
MAZE Financial Highlights
Over the last trailing twelve months MAZE reported a non-GAAP Earnings per Share(EPS) of -20.9. The EPS increased by 103.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.03% | ||
| ROA | 0.81% | ||
| ROE | 0.9% | ||
| Debt/Equity | 0 |
MAZE Forecast & Estimates
12 analysts have analysed MAZE and the average price target is 47.05 USD. This implies a price increase of 1.11% is expected in the next year compared to the current price of 46.53.
For the next year, analysts expect an EPS growth of 86.64% and a revenue growth -100% for MAZE
MAZE Ownership
MAZE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.48 | 987.10B | ||
| JNJ | JOHNSON & JOHNSON | 21.37 | 555.95B | ||
| MRK | MERCK & CO. INC. | 12.87 | 281.39B | ||
| PFE | PFIZER INC | 8.33 | 151.58B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.78B | ||
| ZTS | ZOETIS INC | 19.71 | 55.06B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 10.31 | 24.45B | ||
| VTRS | VIATRIS INC | 5.87 | 15.76B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.78 | 12.30B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.37B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.50B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 6.35B |
Related stock screener links
About MAZE
Company Profile
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. The company is headquartered in South San Francisco, California and currently employs 125 full-time employees. The company went IPO on 2025-01-31. The firm is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Company Info
MAZE THERAPEUTICS INC
171 Oyster Point Boulevard, Suite 300
South San Francisco CALIFORNIA US
Employees: 125
Phone: 16508505070
MAZE THERAPEUTICS INC / MAZE FAQ
What does MAZE THERAPEUTICS INC do?
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. The company is headquartered in South San Francisco, California and currently employs 125 full-time employees. The company went IPO on 2025-01-31. The firm is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
What is the stock price of MAZE THERAPEUTICS INC today?
The current stock price of MAZE is 46.53 USD. The price increased by 6.77% in the last trading session.
What is the dividend status of MAZE THERAPEUTICS INC?
MAZE does not pay a dividend.
What is the ChartMill rating of MAZE THERAPEUTICS INC stock?
MAZE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Would investing in MAZE THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MAZE.
What is the employee count for MAZE stock?
MAZE THERAPEUTICS INC (MAZE) currently has 125 employees.